TC BioPharm (Holdings) PLC announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000. This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment. The Company expects to implement the improved manufacture process into its current facility in the next 24 months.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 USD | -2.55% | +3.45% | -51.74% |
1st Jan change | Capi. | |
---|---|---|
-51.74% | 4.89M | |
+2.58% | 42.75B | |
+47.70% | 41.61B | |
+12.07% | 41.34B | |
-8.83% | 26.59B | |
+7.82% | 25.49B | |
-22.52% | 18.12B | |
+31.13% | 12.24B | |
-1.54% | 11.76B | |
+9.00% | 11B |
- Stock Market
- Equities
- TCBP Stock
- News TC Biopharm (Holdings) Plc
- TC BioPharm PLC Increases Treatment Capacity with Expanded Manufacturing Process